Gilead Submits NDA for Bulevirtide, First Potential HDV Treatment, Backed by Phase 3 MYR301 Data
Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.
Read MoreALL ABOUT DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Gilead Sciences submitted an NDA to the FDA for bulevirtide 10 mg to treat chronic hepatitis delta virus, supported by Phase 3 MYR301 data.
Read MoreThe FDA extended its review of Aldeyra’s reproxalap for dry eye disease to March 16, 2026, after requesting a clinical study report.
Read MoreThe FDA approved ICOTYDE (icotrokinra) for treating moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg.
Read MoreSignificant strides in pediatric care emerge as the FDA clears ET-600 for arginine vasopressin deficiency—discover what this means for treatment safety and outcomes.
Read MoreAutism spectrum disorder (ASD) is a neurodevelopmental disorder that affects an individual’s social interactions and communication.1 In recent decades, the
Read MoreAn entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark
Read MoreMore than $4.3 billion in opioid settlement money has landed in the hands of city, county and state officials to
Read MoreRaw garlic is compared to roasted, stir-fried, simmered, and jarred garlic. Garlic lowers blood pressure, regulates cholesterol, and stimulates immunity.
Read MoreA wide-ranging lawsuit filed Friday outlines a moneymaking scheme by which large insurance sales agency call centers enrolled people into
Read MoreApril 15, 2024 3 min read Add topic to email alerts Receive an email when new articles are posted on
Read More